In the first big pharmaceutical development of 2023, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for semaglutide as the first injectable antiobesity prescription medication for use in pediatric patients.   Manufactured by Novo Nordisk and sold under the brand name Wegovy, semaglutide is a glucagon-like-peptide-1(GLP-1) agonist which … Continue reading FDA Approves Semaglutide for Pediatric Patients